Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Merck
Colorcon
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Nedaplatin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Nedaplatin: Sponsors, patents, clinical trial progress

Nedaplatin is an investigational drug.

There have been 38 clinical trials for Nedaplatin. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.

The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Chinese Academy of Medical Sciences, and Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

There are two US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Nedaplatin
TitleSponsorPhase
Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaJiangsu HengRui Medicine Co., Ltd.Phase 2
Single-arm, Open-label, Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital of Zhengzhou UniversityPhase 2
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Patients With LA-NPCFuzhou General HospitalPhase 2

See all Nedaplatin clinical trials

Clinical Trial Summary for Nedaplatin

Top disease conditions for Nedaplatin
Top clinical trial sponsors for Nedaplatin

See all Nedaplatin clinical trials

US Patents for Nedaplatin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nedaplatin   Start Trial Estrogen-linked platinum (II) complexes as anticancer agents Berube; Gervais (Trois-Riviere, CA)   Start Trial
Nedaplatin   Start Trial Macromolecular platinum chelates Access Pharmaceuticals, Inc. (Dallas, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Boehringer Ingelheim
Baxter
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.